Targeting bone marrow mesenchymal stromal cell-derived IL-6 to overcome acute myeloid leukemia chemoresistance.
Diyu Hou, Danni Cai, Wei Dai...
https://pubmed.ncbi.nlm.nih.gov/40668612Actively Recruiting
Age: 18Years +
All Genders
ID06486350
Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients
Led by Fujian Medical University Union Hospital · Updated on 2024-07-03
72
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute myeloid leukemia (AML) is a cancer that originates from immature blood cells and has a low five-year survival rate of about 30%. This research aims to explore the relationship between levels of interleukin-6 (IL-6) in bone marrow and how sensitive AML is to chemotherapy. Elevated IL-6 has been linked to chemotherapy resistance and worse outcomes, but its role as a marker for treatment response is not fully understood. In this observational study, bone marrow supernatant samples will be collected from adult AML patients to measure IL-6 levels. The study investigates whether higher IL-6 levels predict poorer responses to standard chemotherapy. There are no treatment interventions; instead, the study focuses on analyzing these samples to identify potential markers that could help personalize AML treatment. Participants will provide bone marrow samples and be monitored for treatment response over time. The main outcome measured is the overall response rate after one year, with secondary outcomes including complete remission, incomplete remission, partial remission, and overall survival over two years. The study includes careful clinical evaluation and follows patients to assess how IL-6 levels relate to chemotherapy sensitivity and long-term outcomes.
CONDITIONS
Brief Title
IL-6: A Marker for AML Chemo Sensitivity
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis matches Chinese guidelines for adult AML (not APL) (2023)
- First onset of AML, no prior chemotherapy for this disease
- Participation with family members and signed informed consent
You will not qualify if you...
- Concurrent cancers requiring treatment
- Infectious diseases including SARS, viral hepatitis, or HIV/AIDS
- Major surgery within 21 days prior to study
- Performance Status score greater than 3
- Severe liver or kidney dysfunction or serious infection
- Severe psychiatric illness affecting understanding or voluntary participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Sample Collection
Duration - Up to 1 year
Participants provide bone marrow supernatant samples to measure IL-6 levels and evaluate chemotherapy sensitivity.
Long-term Monitoring
Duration - Up to 2 years
Participants are observed over time to assess treatment outcomes such as response rates and survival.
Trial Site Locations
Total: 1 location
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
Loading map...
Research Team
H
Huifang Huang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here